Phage Lytic Enzyme Cpl-1 for Antibacterial Therapy in Experimental Pneumococcal Meningitis

    loading  Checking for direct PDF access through Ovid

Abstract

Treatment of bacterial meningitis caused byStreptococcus pneumoniaeis increasingly difficult, because of emerging resistance to antibiotics. Recombinant Cpl-1, a phage lysin specific forS. pneumoniae, was evaluated for antimicrobial therapy in experimental pneumococcal meningitis using infant Wistar rats. A single intracisternal injection (20 mg/kg) of Cpl-1 resulted in a rapid (within 30 min) decrease in pneumococci in cerebrospinal fluid (CSF) by 3 orders of magnitude lasting for 2 h. Intraperitoneal administration of Cpl-1 (200 mg/kg) led to an antibacterial effect in CSF of 2 orders of magnitude for 3 h. Cpl-1 may hold promise as an alternative treatment option in pneumococcal meningitis.

Related Topics

    loading  Loading Related Articles